Drugmakers aim for new kind of cholesterol drug

	Tweet

AstraZeneca Plc has signed a deal with Avanir Pharmaceuticals to develop a new kind of drug that may reverse cholesterol build-up inside blood vessels.

The idea is to treat cardiovascular disease by targeting a biological pathway that enhances the flow of cholesterol away from blood vessel walls, where it can lead to the build-up of life-threatening plaques.

If successful, this could potentially reverse existing vascular disease, while current agents have to date been shown only to prevent disease progression.

Because of the novel action, so-called Reverse Cholesterol Transport (RCT) medicines may eventually be given in addition to existing cholesterol drugs, which work by either inhibiting the synthesis of cholesterol or by blocking its absorption from the gut.

AstraZeneca, which already sells the cholesterol fighting statin drug Crestor, will be responsible for developing the new generation of RCT enhancing compounds discovered by Avanir scientists.

Lipitor is used for those who have abnormally High cholesterol levels. When taken together with a low-fat diet, this medicine can effectively reduce LDL cholesterol, commonly referred to as the “bad” cholesterol, triglyceride levels, and total cholesterol, while increasing the HDL, or “good” cholesterol.

How to order Lipitor online

Europe’s third largest drugmaker said on Monday that Avanir could receive milestone payments of $330 million under the deal, in addition to an upfront payment of $10 million, lifting shares in the U.S. firm by around 5 percent.

The San Diego, California-based company will also be entitled to stepped royalties, rising from single-digit to low double-digit percentage rates depending on sales achieved.

But those payouts depend on the drug being approved and launched, which is still many years away, since the partners only expect to be ready to apply to start testing their experimental medicine in humans later this year.

Other companies are also working on ways to improve the body’s removal of “bad" LDL cholesterol. Pfizer Inc is currently undertaking final phase III studies of torcetrapib, a new drug that works by blocking a protein in the liver that transfers cholesterol.

An AstraZeneca spokesman said Avanir’s RCT approach was more direct in its action, since it mimicked a naturally occurring body process to remove bad cholesterol.

RELATED STORIES:
FDA Approves Relenza for Prevention of Seasonal Flu   FDA Has Sweet News for Consumers of Sugar Substitutes   Potential new drug for treating all forms of tuberculosis   FDA advisory panel recommends adding warning label to Tamoxifen   Drug use in strict Singapore waning, gov’t says   FDA wants asthma drug withdrawn   FDA approves Exelon to treat dementia of Parkinson’s disease   Counterfeit Cialis recalled in Britain   Millennium says Velcade works in all myeloma stages   New TB vaccine promising in early clinical trials   FDA nominee stalled over “morning after” pill   Many older COX-2 drug patients take aspirin - study

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]